Expression of Cripto-1 in the placenta and its role in placenta accreta and placenta previa
Abstract
Objectives: This study Aims to explore the role of placental Cripto-1 in the incidence of an adherent placenta.
Material and methods: Ten pregnant women with placenta increta, 20 pregnant women with placenta previa and 30 women with normal pregnant were enrolled in this study. Reverse transcription-polymerase chain reaction (RT-PCR) was used to measure the expression of Cripto-1 in the placenta while as the analysis of placental Cripto-1 was performed by Western blotting
Results: The placenta increta group showed higher levels of Cripto-1 in the center of the increta as compared to the non-implantation area. The level of placental Cripto-1 in the placenta increta was higher than that of the placenta accrete. The expression of placental Cripto-1 in the placenta increta and placenta previa groups was higher than that of control.
Conclusions: Placental Cripto-1 is involved in the regulation of placental tissue invasion. Additionally, excessive placental growth or penetration into the myometrium are likely to be involved in the development of placenta increta.
Keywords: Cripto-1placenta incretaplacenta previapathogenesispregnancy
References
- Lim BH, Palacios-Jaraquemada JM. The morbidly adherent placenta--a continuing diagnostic and management challenge. BJOG. 2015; 122(12): 1673.
- Garmi G, Salim R. Epidemiology, etiology, diagnosis, and management of placenta accreta. Obstet Gynecol Int. 2012; 2012: 873929.
- Leveno KJ, Cunningham FG, Norman FG, et al. Williams Manual of Obstetrics, 24 st edition. McGraw-Hill Education - Europe .
- Dunjin C, Chunhong S. Placenta Accreta.Chunhong S. ed. Hunan Science and Technology Press, Changsha : 1–6.
- Sakinci M, Kuru O, Tosun M, et al. Clinical analysis of emergency peripartum hysterectomies in a tertiary center. Clin Exp Obstet Gynecol. 2014; 41(6): 654–658.
- Parra-Herran C, Djordjevic B. Histopathology of Placenta Creta: Chorionic Villi Intrusion into Myometrial Vascular Spaces and Extravillous Trophoblast Proliferation are Frequent and Specific Findings With Implications for Diagnosis and Pathogenesis. Int J Gynecol Pathol. 2016; 35(6): 497–508.
- Ciccodicola A, Dono R, Obici S, et al. Molecular characterization of a gene of the 'EGF family' expressed in undifferentiated human NTERA2 teratocarcinoma cells. EMBO J. 1989; 8(7): 1987–1991.
- Bandeira CL, Urban Borbely A, Pulcineli Vieira Francisco R, et al. Tumorigenic factor CRIPTO-1 is immunolocalized in extravillous cytotrophoblast in placenta creta. Biomed Res Int. 2014; 2014: 892856.
- Kim KR, Jun SY, Kim JY, et al. Implantation site intermediate trophoblasts in placenta cretas. Mod Pathol. 2004; 17(12): 1483–1490.
- Wendt MK, Allington TM, Schiemann WP. Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol. 2009; 5(8): 1145–1168.
- Qinjian Z, Jianying Y. Role of E-cadherin in Placenta Accreta [J]. Chinese Journal of Perinatal Medicine. 2015; 4: 306–309.
- Bianco C, Strizzi L, Ebert A, et al. Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst. 2005; 97(2): 132–141.
- Gray PC, Vale W. Cripto/GRP78 modulation of the TGF-β pathway in development and oncogenesis. FEBS Lett. 2012; 586(14): 1836–1845.
- Wallace AE, Fraser R, Cartwright JE. Extravillous trophoblast and decidual natural killer cells: a remodelling partnership. Hum Reprod Update. 2012; 18(4): 458–471.
- Lee CC, Jan HJ, Lai JH, et al. Nodal promotes growth and invasion in human gliomas. Oncogene. 2010; 29(21): 3110–3123.
